- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01793948
Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer
A Double Blind Prospective Study of Metformin vs. Placebo in Overweight or Obese Post-menopausal Women at Elevated Risk for Breast Cancer
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVES:
I. To determine the changes in the signal pathway profiling of breast tissue using reverse phase proteomics in tissue biopsy of overweight or obese women at elevated risk for breast cancer treated with metformin (metformin hydrochloride) (850mg orally twice a day) for 12 cycles.
SECONDARY OBJECTIVES:
I. To determine the effect of metformin on breast tissue density of overweight or obese women at elevated risk for breast cancer using qualitative mammographic fat density criteria.
II. To determine the effect of metformin on the insulin axis in serum of overweight or obese women at elevated risk for breast cancer treated with metformin (850mg orally twice a day) for 12 cycles.
III. To determine the toxicities associated with metformin.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
ARM II: Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter. Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6 months for up to 5 years.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiesteder
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients must be post-menopausal women; post-menopausal women are defined as: (1) those >= 50 years of age who had not menstruated during the preceding 12 months or who had castrate follicle-stimulating hormone levels (> 40 IU/L), (2) those who had undergone a bilateral oophorectomy
Patients must be at elevated risk for breast cancer based on strong family history or a history of breast biopsy documenting atypical hyperplasia anytime in the past; for this study strong family history is defined as having:
- 1 first-degree (parent, offspring, sibling) relative =< 50 years old when diagnosed with breast cancer, or
- >= 2 first-degree relatives of any age when diagnosed with breast cancer, or
- >= 2 second-degree (aunts, uncles, grandparents, grandchildren, nieces, nephews, or half-siblings) maternal or paternal relatives diagnosed with breast cancer and at least 1 diagnosed at =< 50 years of age
Patients must have a body mass index (BMI) >= 25.0 as calculated by the formula: weight in pounds / height squared x 703 = BMI; a BMI of:
- 18.5-24.9 is considered normal;
- 25.0-29.9 is considered overweight;
- 30.0+ is regarded as obese
- Patients must be willing to complete a bilateral mammogram at baseline with repeat exam after 12 cycles of protocol therapy; patients who have had a mammogram within 1 month prior to registration to protocol therapy will not need to repeat the exam
- Patients must be willing to provide a core tissue biopsy at baseline and with repeat tissue collection after 12 cycles of protocol therapy
- White blood cell (WBC) >= 3.0 x 109/L
- Granulocytes (polymorphs + bands) >= 1.5 x 109/L
- Platelets >= 100 x 109/L
- Hemoglobin >= 110 g/L
- Aspartate aminotransferase (AST) =< 1.8 X upper limit of normal (ULN)
- Alanine aminotransferase (ALT) =< 1.8 X ULN
- Alkaline phosphatase =< 2 X ULN
- Serum creatinine =< 115 umol/L (1.3mg/dL)
- Serum bilirubin =< institution ULN (except for subjects with Gilbert's Disease who are eligible despite elevated serum bilirubin level)
- 12 hour fasting glucose level < 7.0 mmol/L
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1 within 28 days of registration
- Life expectancy of >= 5 years
- Subjects must be accessible for treatment, adverse event tracking and follow-up as determined by the treating physician
- Subject consent and authorization for the release of health information must be obtained according to local institutional guidelines
Exclusion Criteria:
- No history of any malignancy except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for >= 5 years
- No known diabetes (type 1 or 2) or baseline fasting glucose >= 7.0 mmol/L
- No known hypersensitivity or intolerance to metformin
- No condition associated with increased risk of metformin-associated lactic acidosis (e.g. congestive heart failure defined as New York Heart Association [NYHA] class III or IV functional status, history of acidosis of any type; habitual intake of 3 or more alcoholic beverages per day)
- No current treatment with metformin, sulfonylureas, thiazolidinediones or insulin for any reason
- No breastfeeding
- No concurrent or planned participation in randomized trials of weight loss or exercise interventions or trials targeting insulin, insulin-like growth factor 1 (IGF-1) or their receptors
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Arm I (metformin hydrochloride)
Patients receive metformin hydrochloride by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter.
Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
|
Korrelative undersøgelser
Givet PO
Andre navne:
|
Placebo komparator: Arm II (placebo)
Patients receive placebo by mouth once daily on days 1-30 in course 1 and twice daily on days 1-30 thereafter.
Treatment repeats every 30 days for 12 courses in the absence of disease progression or unacceptable toxicity.
|
Korrelative undersøgelser
Givet PO
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in the phosphorylation of proteins after metformin exposure
Tidsramme: Baseline and 12 months
|
Reverse phase proteomic assays (RPPA) will be performed to measure changes in the phosphorylation of proteins after metformin exposure.
Changes in the phosphorylation of proteins after metformin exposure will be calculated and compared using two-sample t-tests.
As a supplemental analysis, analysis of covariance (ANCOVA) will be used to model the 12 month levels adjusted for baseline.
Assumptions for analysis will be checked and non-parametric methods used if needed; however it is expected that the data will be normally distributed on the log scale.
|
Baseline and 12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Changes in ordinal level of breast density
Tidsramme: Baseline and 12 months
|
Changes in ordinal level of breast density will be performed using the breast density criteria previously established by Boyd and colleagues (New England Journal of Medicine 2007).
Each image will be grouped into one of six categories: 0%, <10%, 10-25%, 25-50%, 50-75% and >75%.
Changes will be compared between the two groups using Wilcoxon Rank-Sum tests.
|
Baseline and 12 months
|
Proportion of patients experiencing adverse events assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Tidsramme: Up to 30 days
|
Will be tabulated by arm and grade.
|
Up to 30 days
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Anna Maria Storniolo, MD, Indiana University Melvin and Bren Simon Cancer Center
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- IUCRO-0365
- NCI-2013-00422 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- 1301010355 (Anden identifikator: Indiana University IRB)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med laboratoriebiomarkøranalyse
-
Liao Jian AnRekrutteringHoved- og halskræftTaiwan
-
Fondation LenvalTrukket tilbage
-
Progenity, Inc.AfsluttetDowns syndrom | Aneuploidi | DiGeorges syndrom | Turners syndrom | Klinefelters syndrom | Kromosom sletning | Edwards syndrom | Patau syndromForenede Stater
-
IRCCS Eugenio MedeaRekrutteringAutismespektrumforstyrrelse | Tidlig indsatsItalien
-
Oregon Health and Science University4DMedicalTilmelding efter invitationLungesygdomme | KOL | Luftvejssygdom | DyspnøForenede Stater
-
IRCCS Eugenio MedeaRekrutteringCerebral Parese | Erhvervet hjerneskadeItalien
-
Modarres HospitalAfsluttetKomplikationer | Billedstyret biopsi | Nyre GlomerulusIran, Islamisk Republik
-
Healthy.io Ltd.Afsluttet
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadUkendtErhvervsmæssig eksponering | Muskuloskeletal sygdomChile
-
Alcon ResearchAfsluttet